Table 1.

Demographic and baseline characteristics of patients entered into the lenercept MS trial

CharacteristicsPlacebo, n = 44Lenercept, mg
10, n = 4450, n = 40100, n = 40
SPMS = secondary progressive MS; EDSS = Expanded Disability Status Scale; NRS = Neurological Rating Scale.
% Female66807873
Age, y, mean (range)36.5 (21–50)34.6 (23–51)35.1 (19–47)34.9 (21–51)
% White9810010093
No. with SPMS105104
Mean (range) no. exacerbations in prior 2 years2.7 (2–5)2.8 (2–8)2.8 (2–8)3.0 (2–6)
EDSS, mean (range)2.45 (0–5.5)2.52 (0–5.0)2.83 (1.0–5.5)2.55 (0–5.5)
NRS, mean (range)83.2 (51–100)83.7 (44–100)81.8 (54–100)83.0 (57–99)